Ransys AM

Amlodipine is a dihydropyridine calcium channel blocker. It stops calcium ions from moving across the cell membrane into vascular smooth muscle and cardiac muscle, and its effect is greater on vascular smooth muscle cells than on cardiac muscle cells. Amlodipine is a peripheral arterial vasodilator. It acts directly on vascular smooth muscle, which lowers peripheral vascular resistance and so reduces blood pressure.

Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE). It is a potent vasoconstrictor, the primary vasoactive hormone of the Renin-angiotensin system, and an important part of the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Olmesartan Medoxomil blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. It does this by selectively blocking the binding of angiotensin II to the AT1 receptor, which is found in many tissues (e.g. vascular smooth muscle, adrenal gland). In vitro binding studies show that Olmesartan Medoxomil is a reversible, competitive inhibitor of the AT1 receptor. It does not inhibit ACE (kinase II, the enzyme that converts angiotensin I to angiotensin II and breaks down bradykinin).

Amlodipine and Olmesartan Medoxomil is Pregnancy Category D. Don't use this combination in the 2nd and 3rd trimester, because it can cause fetal death. If pregnancy is detected, stop the combination as soon as possible.

Nobody knows yet whether olmesartan and amlodipine pass into human milk. Because they could harm a nursing infant, the decision has to be made either to stop nursing or to stop the medicine, and that choice should take into account how important the medicine is to the mother.

Pediatric use: Amlodipine Besilate + Olmesartan Medoxomil has not been shown to be safe or effective in pediatric patients.

Geriatric use: Researchers saw no overall differences in safety or effectiveness between patients aged 65 years or older and younger patients.

Renal impairment: No studies have been done in patients with renal impairment.

Hepatic impairment: Starting treatment with this medicine is not recommended in patients with impaired liver function.

মানুষের ক্ষেত্রে মাত্রাতিরিক্ত সেবনের (ওভারডোজ) কোনো তথ্য নেই।

Store below 30°C, away from light, and out of children's reach.